TCRT_OUT_1 [2025-04-01 12:28:27 -0400] 1996 Bytes | 558 tokens | Cum: 558 tkns (6.98% of 8k)
==========================================================================

Listen up, partner—it's 12:28:26 PM on Tue Apr 01, 2025 -0400, and I’m revved up about Alaunos Therapeutics (TCRT), climbing from 1.47 to 2.4299. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Alaunos Therapeutics:

C1 - Oct-11-24 08:57AM - Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy
C2 - May-15-24 10:55PM - TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024
C3 - Apr-08-24 12:52PM - TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023
C4 - Dec-18-23 07:57AM - Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
C5 - Nov-14-23 07:56AM - Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
C6 - Nov-14-23 07:56AM 07:30AM - Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
C7 - Aug-14-23 04:05PM - Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
C8 - Jun-29-23 07:00AM - Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Alaunos Therapeutics (TCRT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TCRT_OUT_3 [2025-04-01 12:28:32 -0400] 1100 Bytes | 267 tokens | Cum: 827 tkns (10.34% of 8k)
==========================================================================

Showing C1 (chunk 1 of 2): C1:
**Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy**
Date: Oct-11-24 08:57AM
Source: (TipRanks)
URL: https://finance.yahoo.com/news/alaunos-therapeutics-ends-licensing-deal-125737537.html

The latest announcement is out from Alaunos Therapeutics ((TCRT)).

Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agreement with Precigen, Inc. for developing neoantigen T-cell receptors to treat solid tumor cancers, signaling a shift in strategic priorities. The original agreement, in place since 2018, will end following Alaunos’s assessment of its business goals and the impending patent expiration of the Sleeping Beauty gene transfer platform in 2026. Despite this, Alaunos is actively pursuing its intellectual property rights for certain T-cell receptors and exploring various strategic options, including mergers and partnerships, to advance its business in

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_5 [2025-04-01 12:28:35 -0400] 278 Bytes | 89 tokens | Cum: 1010 tkns (12.62% of 8k)
==========================================================================

Showing C1 (chunk 2 of 2): terests.

See more insights into TCRT stock onTipRanks’ Stock Analysis page.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_7 [2025-04-01 12:28:36 -0400] 462 Bytes | 118 tokens | Cum: 1192 tkns (14.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-28T11:03:20Z - North American Morning Briefing: Tariff Jitters -2-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TCRT_OUT_9 [2025-04-01 12:28:44 -0400] 1098 Bytes | 336 tokens | Cum: 1530 tkns (19.12% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**North American Morning Briefing: Tariff Jitters -2-**Date: 2025-03-28Source: {'uri': 'morningstar.com', 'dataType': 'news', 'title': 'Morningstar'}URL: https://www.morningstar.com/news/dow-jones/202503283256/north-american-morning-briefing-tariff-jitters-200:01/UK: Mar CBI Growth Indicator and Service Sector Survey

07:45/FRA: Feb Household consumption expenditure in manufactured goods

07:45/FRA: Mar Provisional CPI

08:55/GER: Mar Labour market statistics (incl unemployment)

14:00/US: Mar University of Michigan Survey of Consumers - final

All times in GMT. Powered by Kantar Media and Dow Jones.

Adverum Biotechnologies Inc (ADVM) is expected to report for 4Q.

Aerovate Therapeutics Inc (AVTE) is expected to report $-0.19 for 4Q.

AgEagle Aerial Systems Inc (UAVS) is expected to report for 4Q.

Aimia Inc (AIM.T) is expected to report for 4Q.

Alaunos Therapeutics Inc (TCRT) is e

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_11 [2025-04-01 12:28:44 -0400] 1084 Bytes | 325 tokens | Cum: 2006 tkns (25.07% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-02-01T18:17:44Z - Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B2 - 2024-01-10T18:06:18Z - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B3 - 2024-01-05T13:03:11Z - Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
B4 - 2023-12-19T18:34:55Z - Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-12-19T13:09:17Z - Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
B6 - 2023-12-18T18:05:04Z - Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TCRT_OUT_13 [2025-04-01 12:28:49 -0400] 1098 Bytes | 311 tokens | Cum: 2319 tkns (28.99% of 8k)
==========================================================================

Showing B3 (chunk 1 of 2): B3:
**Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/01/36508372/why-dermata-therapeutics-shares-are-trading-higher-by-over-57-here-are-20-stocks-moving-premarketShares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers

Ainos, Inc.(NASDAQ: AIMD) gained 142.6% to $4.20 in pre-market trading after falling more than 12% on Thursday.
Safe and Green Development Corporation (NASDAQ: SGD) shares rose 34.5% to $1.83 in pre-market trading. Safe And Green Development recently

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_15 [2025-04-01 12:28:50 -0400] 1076 Bytes | 264 tokens | Cum: 2707 tkns (33.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S2 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Fin Stmnts

Alaunos Therapeutics, Inc.

COND BAL SHEETS

(unaudited)

(in thousands, except share and per share data)

September 30,

December 31,

ASSETS:

Curr assets:

Cash and cash equiv

$...

S3 - 2024-10-10 8-K Item 2.02 Results of Oper and Fin Cond

Alaunos continues to progress and evaluate its internally developed small molecule oral obesity program. The aim of this program is to develop a drug for obesity with a differentiated profile relative to currently marketed...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TCRT_OUT_17 [2025-04-01 12:28:51 -0400] 1098 Bytes | 228 tokens | Cum: 2937 tkns (36.71% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results, levels of activity, performance or achievements could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those under Risk Factors included in Part I, Item 1A and under Special Note Regarding Forward-Looking Statements or in other parts of this Annual Report on Form 10-K. All share amounts pre

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_19 [2025-04-01 12:29:02 -0400] 4161 Bytes | 1174 tokens | Cum: 4113 tkns (51.41% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 759,458 | Perf Month: 25.51% | Option/Short: No / Yes | Sales Y/Y TTM: -60.00% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 13.52K | Perf Quarter: 7.09% | Short Float: 3.75% | ROE: -141.73% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 125.65 | Index: - | Short Ratio: 3.83 | ROI: -432.49% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 69.82 | Market Cap: 3.15M | Short Interest: 0.05M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.16 | Shs Outstand: 1.60M | Beta: -0.74 | EPS Surprise: -14.29% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 29.07% | Shs Float: 1.38M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: 23.08% | Inst Own: 4.51% | Sales past 5Y: 133.59% | Earnings: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -29.18% | Insider Own: 13.75% | Employees: - | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: 22.34% | Insider Trans: -1.34% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 6000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -11780000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.22
Average Volume: 89678.05
30-Day High: 2.22
30-Day Low: 1.4301

[Detailed Financials: Q3 2024]
- Total Assets: $3,550,000.0
- Total Liabilities: $826,000
- Total Equity: $2,724,000.0
- Current Assets: $3,550,000.0
- Current Liabilities: $826,000

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.7

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-781,000

[Detailed Financials: Q2 2024]
- Total Assets: $4,678,000.0
- Total Liabilities: $907,000
- Total Equity: $3,771,000.0
- Current Assets: $4,678,000.0
- Current Liabilities: $907,000

[Income Statement: Q2 2024]
- Revenue: $4,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.71

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,681,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TCRT_OUT_21 [2025-04-01 12:29:07 -0400] 676 Bytes | 167 tokens | Cum: 4507 tkns (56.34% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TCRT_IN_23 [2025-04-01 12:29:07 -0400] 126 Bytes | 29 tokens | Cum: 4610 tkns (57.63% of 8k)
==========================================================================

====================================
[2025-04-01 12:29:07] # Analysis Completed
Elapsed Time: 41.08 seconds